

Age-relatedMacularDegeneration (ARMD) Drugs Market - Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/A578F919752BEN.html>

Date: February 2022

Pages: 63

Price: US\$ 3,250.00 (Single User License)

ID: A578F919752BEN

Abstracts

This report contains market size and forecasts of Age-relatedMacularDegeneration (ARMD) Drugs in Global, including the following market information:

Global Age-relatedMacularDegeneration (ARMD) Drugs Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Age-relatedMacularDegeneration (ARMD) Drugs market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Anti VEGF Drugs Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Age-relatedMacularDegeneration (ARMD) Drugs include Roche, Regeneron Pharmaceuticals, Bayer, Santen Oy, Kanghong Pharmaceuticals, Novartis, Eli Lilly and Company, TRACON Pharmaceuticals and Pfizer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Age-relatedMacularDegeneration (ARMD) Drugs companies, and industry experts on this

industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Age-relatedMacularDegeneration (ARMD) Drugs Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Age-relatedMacularDegeneration (ARMD) Drugs Market Segment Percentages, by Type, 2021 (%)

Anti VEGF Drugs

Photosensitive Drugs

Others

Global Age-relatedMacularDegeneration (ARMD) Drugs Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Age-relatedMacularDegeneration (ARMD) Drugs Market Segment Percentages, by Application, 2021 (%)

Exudative ARMD

Atrophy ARMD

Global Age-relatedMacularDegeneration (ARMD) Drugs Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Age-relatedMacularDegeneration (ARMD) Drugs Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Age-relatedMacularDegeneration (ARMD) Drugs revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Age-relatedMacularDegeneration (ARMD) Drugs revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Roche

Regeneron Pharmaceuticals

Bayer

Santen Oy

Kanghong Pharmaceuticals

Novartis

Eli Lilly and Company

TRACON Pharmaceuticals

Pfizer

GSK

BIOCAD

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Age-relatedMacularDegeneration (ARMD) Drugs Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL AGE-RELATEDMACULARDEGENERATION (ARMD) DRUGS OVERALL MARKET SIZE

- 2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size: 2021 VS 2028
- 2.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Age-relatedMacularDegeneration (ARMD) Drugs Players in Global Market
- 3.2 Top Global Age-relatedMacularDegeneration (ARMD) Drugs Companies Ranked by Revenue
- 3.3 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Companies
- 3.4 Top 3 and Top 5 Age-relatedMacularDegeneration (ARMD) Drugs Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Age-relatedMacularDegeneration (ARMD) Drugs Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Age-relatedMacularDegeneration (ARMD) Drugs Players in Global Market
 - 3.6.1 List of Global Tier 1 Age-relatedMacularDegeneration (ARMD) Drugs Companies

3.6.2 List of Global Tier 2 and Tier 3 Age-relatedMacularDegeneration (ARMD) Drugs Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Markets, 2021 & 2028

4.1.2 Anti VEGF Drugs

4.1.3 Photosensitive Drugs

4.1.4 Others

4.2 By Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue & Forecasts

4.2.1 By Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2017-2022

4.2.2 By Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2023-2028

4.2.3 By Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2021 & 2028

5.1.2 Exudative ARMD

5.1.3 Atrophy ARMD

5.2 By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue & Forecasts

5.2.1 By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2017-2022

5.2.2 By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2023-2028

5.2.3 By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size,

2021 & 2028

6.2 By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue & Forecasts

6.2.1 By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2017-2022

6.2.2 By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2023-2028

6.2.3 By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2017-2028

6.3.2 US Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2017-2028

6.3.3 Canada Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2017-2028

6.3.4 Mexico Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2017-2028

6.4.2 Germany Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2017-2028

6.4.3 France Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2017-2028

6.4.4 U.K. Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2017-2028

6.4.5 Italy Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2017-2028

6.4.6 Russia Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2017-2028

6.4.7 Nordic Countries Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2017-2028

6.4.8 Benelux Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2017-2028

6.5.2 China Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2017-2028

6.5.3 Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2017-2028

6.5.4 South Korea Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2017-2028

6.5.5 Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2017-2028

6.5.6 India Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2017-2028

6.6.2 Brazil Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2017-2028

6.6.3 Argentina Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2017-2028

6.7.2 Turkey Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2017-2028

6.7.3 Israel Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2017-2028

6.7.4 Saudi Arabia Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2017-2028

6.7.5 UAE Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Roche

7.1.1 Roche Corporate Summary

7.1.2 Roche Business Overview

7.1.3 Roche Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings

7.1.4 Roche Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2017-2022)

7.1.5 Roche Key News

7.2 Regeneron Pharmaceuticals

7.2.1 Regeneron Pharmaceuticals Corporate Summary

7.2.2 Regeneron Pharmaceuticals Business Overview

7.2.3 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings

7.2.4 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2017-2022)

7.2.5 Regeneron Pharmaceuticals Key News

7.3 Bayer

7.3.1 Bayer Corporate Summary

7.3.2 Bayer Business Overview

7.3.3 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings

7.3.4 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2017-2022)

7.3.5 Bayer Key News

7.4 Santen Oy

7.4.1 Santen Oy Corporate Summary

7.4.2 Santen Oy Business Overview

7.4.3 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings

7.4.4 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2017-2022)

7.4.5 Santen Oy Key News

7.5 Kanghong Pharmaceuticals

7.5.1 Kanghong Pharmaceuticals Corporate Summary

7.5.2 Kanghong Pharmaceuticals Business Overview

7.5.3 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings

7.5.4 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2017-2022)

7.5.5 Kanghong Pharmaceuticals Key News

7.6 Novartis

7.6.1 Novartis Corporate Summary

7.6.2 Novartis Business Overview

7.6.3 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings

7.6.4 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2017-2022)

7.6.5 Novartis Key News

7.7 Eli Lilly and Company

7.7.1 Eli Lilly and Company Corporate Summary

7.7.2 Eli Lilly and Company Business Overview

7.7.3 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings

7.7.4 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2017-2022)

7.7.5 Eli Lilly and Company Key News

7.8 TRACON Pharmaceuticals

7.8.1 TRACON Pharmaceuticals Corporate Summary

7.8.2 TRACON Pharmaceuticals Business Overview

7.8.3 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings

7.8.4 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2017-2022)

7.8.5 TRACON Pharmaceuticals Key News

7.9 Pfizer

7.9.1 Pfizer Corporate Summary

7.9.2 Pfizer Business Overview

7.9.3 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings

7.9.4 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2017-2022)

7.9.5 Pfizer Key News

7.10 GSK

7.10.1 GSK Corporate Summary

7.10.2 GSK Business Overview

7.10.3 GSK Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings

7.10.4 GSK Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2017-2022)

7.10.5 GSK Key News

7.11 BIOCAD

7.11.1 BIOCAD Corporate Summary

7.11.2 BIOCAD Business Overview

7.11.3 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings

7.11.4 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2017-2022)

7.11.5 BIOCAD Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Age-relatedMacularDegeneration (ARMD) Drugs Market Opportunities & Trends in Global Market

Table 2. Age-relatedMacularDegeneration (ARMD) Drugs Market Drivers in Global Market

Table 3. Age-relatedMacularDegeneration (ARMD) Drugs Market Restraints in Global Market

Table 4. Key Players of Age-relatedMacularDegeneration (ARMD) Drugs in Global Market

Table 5. Top Age-relatedMacularDegeneration (ARMD) Drugs Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Companies, 2017-2022

Table 8. Global Companies Age-relatedMacularDegeneration (ARMD) Drugs Product Type

Table 9. List of Global Tier 1 Age-relatedMacularDegeneration (ARMD) Drugs Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Age-relatedMacularDegeneration (ARMD) Drugs Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue

(US\$, Mn), 2017-2022

Table 19. By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2023-2028

Table 30. Roche Corporate Summary

Table 31. Roche Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings

Table 32. Roche Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US\$, Mn), (2017-2022)

Table 33. Regeneron Pharmaceuticals Corporate Summary

Table 34. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings

Table 35. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US\$, Mn), (2017-2022)

Table 36. Bayer Corporate Summary

Table 37. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings

Table 38. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US\$, Mn), (2017-2022)

Table 39. Santen Oy Corporate Summary

Table 40. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings

Table 41. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US\$, Mn), (2017-2022)

Table 42. Kanghong Pharmaceuticals Corporate Summary

Table 43. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings

Table 44. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US\$, Mn), (2017-2022)

Table 45. Novartis Corporate Summary

Table 46. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings

Table 47. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US\$, Mn), (2017-2022)

Table 48. Eli Lilly and Company Corporate Summary

Table 49. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings

Table 50. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US\$, Mn), (2017-2022)

Table 51. TRACON Pharmaceuticals Corporate Summary

Table 52. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings

Table 53. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US\$, Mn), (2017-2022)

Table 54. Pfizer Corporate Summary

Table 55. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings

Table 56. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US\$, Mn), (2017-2022)

Table 57. GSK Corporate Summary

Table 58. GSK Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings

Table 59. GSK Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US\$, Mn), (2017-2022)

Table 60. BIOCAD Corporate Summary

Table 61. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings

Table 62. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Age-relatedMacularDegeneration (ARMD) Drugs Segment by Type in 2021

Figure 2. Age-relatedMacularDegeneration (ARMD) Drugs Segment by Application in 2021

Figure 3. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Age-relatedMacularDegeneration (ARMD) Drugs Revenue in 2021

Figure 8. By Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2017-2028

Figure 9. By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2017-2028

Figure 10. By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2017-2028

Figure 11. By Country - North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2017-2028

Figure 12. US Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2017-2028

Figure 16. Germany Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 17. France Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn),

2017-2028

Figure 20. Russia Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2017-2028

Figure 24. China Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 28. India Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2017-2028

Figure 30. Brazil Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2017-2028

Figure 33. Turkey Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 37. Roche Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. GSK Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Age-relatedMacularDegeneration (ARMD) Drugs Market - Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/A578F919752BEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A578F919752BEN.html>